BioPharmSignal logoBioPharmSignal

Biotech News

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

AnaptysBio, Inc. (ANAB)AnaptysBio, Inc.Earnings

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA

Related news

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

HCWBHCW Biologics2026-08-14 19:15 EST

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

XLOXilio Therapeutics2026-08-12 11:30 EST

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

MREOMereo BioPharma2026-08-11 12:15 EST

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

STTKShattuck Labs2026-08-11 10:15 EST

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

APGEApogee Therapeutics2026-08-10 11:00 EST

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

XFORX4 Pharmaceuticals2026-08-06 20:15 EST

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

View all latest news

AnaptysBio, Inc.

Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio. Jemperli Economics Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck...

Recent company news

ANABAnaptysBio, Inc.2026-09-21 20:15 EST

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

ANABAnaptysBio, Inc.2026-09-01 20:15 EST

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

ANABAnaptysBio, Inc.2026-05-11 13:15 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ANABAnaptysBio, Inc.2026-05-04 20:15 EST

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Stock data

Close
55.20 USD
Market cap
1.49B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States